Pin-point™ Technology Licensing is now part of Revvity’s portfolio

Accelerating therapeutic development and reach into the clinic


Gain access to the Pin-point™ base editing platform

Would you like the opportunity to license a novel pathway in the development of cell and gene therapeutic programs? The Pin-point™ base editing system offers the specificity of base editing combined with the potential for multiplex gene editing capabilities, making it a very attractive technology for both cell and gene therapies.
Please contact us if you are interested in deploying base editing in your therapeutic pipeline for cell or gene therapy programs and one of our corporate development partners will be in touch.
Revvity enters license agreement with AstraZeneca
Read the announcement here

Contact us to discuss your project

Required fields marked with * Required